Pancreatic cancer is the fourth leading cause of cancer related death in the United States. There is an urgent need to identify novel biomarkers for early diagnosis and targets for therapeutic interventions. Overexpression of EGFR in PC cells plays a crucial role in the uncontrolled proliferation of neoplastic cells. Amplification or overexpression of the wild-type EGFR (EGFRwt) gene is frequently associated with rearrangements or alternate splicing resulting in the expression of structurally altered EGFR mRNA and protein. EGFRvIII is the most is the most common naturally occurring mutant form of EGFR and is expressed in many cancer types including glioblastoma, breast, ovarian, head and neck, lung and prostate cancer. Although amplification of EGFR and its ligands is well documented in pancreatic cancer, no efforts have been made to study the incidence or involvement of EGFRvIII in pancreatic cancer. Our preliminary results suggest that EGFRvIII is highly expressed in pancreatic cancer tissues. Based on the preliminary findings we hypothesize that """"""""naturally occurring epidermal growth factor receptor variant III (EGFRvIII) contributes to the pathogenesis of pancreatic adenocarcinomas"""""""". To test the hypothesis following specific aims are proposed:
SPECIFIC AIM I will investigate the expression of EGFR and EGFR variants in human pancreatic tumors by reverse transcriptase- polymerase chain reaction (RT-PCR) and immunohistochemical analysis. PCR- amplification will demonstrate the expression of mRNA. Immunohistochemical analysis using a EGFRvIII specific monoclonal antibody will indicate the presence and cellular localization of the EGFRvIII protein.
This aim will provide the information on the incidence of expression of EGFRvIII in human pancreatic tumors.
SPECIFIC AIM II will express EGFRvIII in highly tumorigenic (HPAF) and poorly tumorigenic (MiaPaCa) human pancreatic cancer cell lines and immortalized human pancreatic ductal cells (HTERT/HPNE) to establish its contribution to the malignant phenotype.
This aim will support our prediction that expression of EGFRvIII in cultured immortal pancreatic cells is sufficient to lead to a transformed phenotype;that the cells will gain the ability to form foci in soft agar and to form tumors in nude mice. Taken together, these studies will provide the incidence and function of a novel naturally occurring variant of EGFRvIII in the lethal pancreatic cancer. The long-term goal of this project is to use the newly developed anti-EGFRvIII antibodies for targeted therapy of pancreatic cancer.

Public Health Relevance

Mutant epidermal growth factor receptor, EGFRvIII is an attractive target for targeted therapy due to its tumor-restricted expression and presence of unique antigenic epitopes. In this grant application, we propose to investigate EGFRvIII's expression in pancreatic tumors (various grades of malignancy), its oncogenic function in immortal pancreatic cells, and its effect on tumorigenecity of pancreatic cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
1R03CA139285-01
Application #
7641980
Study Section
Special Emphasis Panel (ZRG1-ONC-U (92))
Program Officer
Sathyamoorthy, Neeraja
Project Start
2009-06-19
Project End
2011-05-31
Budget Start
2009-06-19
Budget End
2010-05-31
Support Year
1
Fiscal Year
2009
Total Cost
$74,250
Indirect Cost
Name
University of Nebraska Medical Center
Department
Biochemistry
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Gupta, Suprit; Batra, Surinder; Jain, Maneesh (2014) Antibody labeling with radioiodine and radiometals. Methods Mol Biol 1141:147-57
Macha, Muzafar A; Rachagani, Satyanarayana; Gupta, Suprit et al. (2013) Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling. Cancer Lett 341:166-77
Jain, Maneesh; Gupta, Suprit; Kaur, Sukhwinder et al. (2013) Emerging trends for radioimmunotherapy in solid tumors. Cancer Biother Radiopharm 28:639-50
Kaur, Sukhwinder; Venktaraman, Ganesh; Jain, Maneesh et al. (2012) Recent trends in antibody-based oncologic imaging. Cancer Lett 315:97-111
Seshacharyulu, Parthasarathy; Ponnusamy, Moorthy P; Haridas, Dhanya et al. (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15-31
Chakraborty, Subhankar; Kaur, Sukhwinder; Guha, Sushovan et al. (2012) The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 1826:129-69
Kaur, Sukhwinder; Baine, Michael J; Jain, Maneesh et al. (2012) Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med 6:597-612
Mukhopadhyay, Partha; Chakraborty, Subhankar; Ponnusamy, Moorthy P et al. (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 1815:224-40
Jain, Maneesh; Venkatraman, Ganesh; Moniaux, Nicolas et al. (2011) Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer. PLoS One 6:e23344